CTOs on the Move

Precigen

www.precigen.com

 
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.precigen.com
  • 20358 Seneca Meadows Parkway
    Germantown, MD USA 20876
  • Phone: 301.556.9900

Executives

Name Title Contact Details

Funding

Precigen raised $35M on 02/03/2020

Similar Companies

Barc USA

Barc USA is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Artisan Pharma

Artisan Pharma is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tyme

TYME, Inc. is a pharmaceutical company focused on creating medicines that specialize in using the body’s immune system to treat diseases. The body has the ability to fight off major diseases and heal itself. Tyme is researching a mechanism that it believes may work alongside the body’s immune system to fight Stage IV Metastatic Cancer. Tyme hopes to provide a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers (breast, lung, prostrate, gastric, esophageal and pancreatic cancers) responsible for 62% of the annual cancer deaths in the United States. The SM-88, Tyme’s proprietary compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. SM-88 is designed to penetrate the living cancer cells and introduce multiple mechanisms to kill the cell. Inducing transfer of electrons in the cancer cells may allow catalyzed external free radicals to react and stress the cell. SM-88 is a combination of low dose agents used for non-cancer treatment.

Angiocrine Bioscience

Transforming medicine through cellular therapies that restore, regenerate, and repair tissues and organs

Strategic Partnerships

Strategic Partnerships, LLC is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.